Federal contract award
75N91019F00138
CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00024 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $24.1M |
| Current contract value | $24.1M |
| Potential contract value / ceiling | $24.1M |
| Start date | Sep 23, 2019 |
| Current end date | Sep 18, 2029 |
| Potential end date | Sep 18, 2029 |
| Latest award activity | May 19, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 19, 2026 | P00012 | $0 | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Sep 17, 2025 | P00011 | $2.5M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Aug 26, 2025 | P00010 | $2.0M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| May 2, 2025 | P00009 | $0 | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Sep 19, 2024 | P00008 | $5.1M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Jul 18, 2024 | P00007 | $0 | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Jun 7, 2024 | P00006 | $0 | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Sep 11, 2023 | P00005 | $1.8M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Jun 28, 2022 | P00004 | $1.3M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| May 18, 2022 | P00003 | $414.9K | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| May 27, 2021 | P00002 | $7.3M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Mar 5, 2021 | P00001 | $218.7K | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
| Sep 20, 2019 | 0 | $3.6M | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS |
Estimated positioning window
Sep 18, 2028 – Mar 18, 2029
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2029-09-18 (1052 days from calculation)
- +15 points
- 240 historical awards in this buyer and category group
- +15 points
- 13 recorded award transactions
- +10 points
- Latest award action: 2026-05-19
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.